» Articles » PMID: 8042235

Transhepatic Metabolism of TNF-alpha, IL-6, and Endotoxin in the Early Hepatic Reperfusion Period After Human Liver Transplantation

Overview
Journal Transplantation
Specialty General Surgery
Date 1994 Jul 27
PMID 8042235
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Several studies have shown that the postoperative course of cytokines such as TNF-alpha or IL-6 is predictive of rejection and infection after human orthotopic liver transplantation (OLT). The aim of this prospective clinical trial was to evaluate the impact of transhepatic metabolism of endotoxin (ET), tumor necrosis-factor-alpha (TNF-alpha), and interleukin-6 (IL-6) after hepatic ischemia/reperfusion on the postoperative graft function. In 13 consecutive elective adult OLT patients with primary grafts, we determined concentrations of ET, TNF-alpha, and IL-6 in the radial artery, portal vein, and right hepatic vein at 1, 4, 7, 10, and 13 min after reperfusion. Of the 13 patients, four had ET levels below the detection limit (< 10 ng/L), and one patient had extremely high ET concentrations (151 ng/L in the hepatic vein). In the remaining patients the mean ET levels were 26 +/- 14, 26 +/- 15, and 24 +/- 14 ng/L in the portal vein, hepatic vein, and in the radial artery, respectively. These values indicate that in patients with a moderately elevated ET level, no transhepatic concentration differences of ET exist. However, in the patient with severe endotoxemia, the liver was apparently an ET-producing organ (HV-P: 29 +/- 13 ng/L). TNF-alpha levels were not measurable in four patients, and varied between 15 and 72 pg/ml (portal vein) in the remaining patients. The transhepatic concentration differences (HV-P and HV-A, respectively) of patients with PNF or dysfunction were higher than in those with "good" or "excellent" graft function (HV-P: 160 +/- 122 pg/ml vs. 7.3 +/- 9.7 pg/ml; P < 0.01 and HV-A: 137 +/- 101 pg/ml vs. 3.9 +/- 12 pg/ml; P < 0.01, respectively). Arterial IL-6 levels were below 88 pg/ml (mean value: 31 +/- 20 pg/ml) at the beginning of the operation, and increased considerably in three patients during the anhepatic phase and after reperfusion. No clinical correlation was found with the transhepatic concentration differences of IL-6. We conclude that in OLT patients without infection no transhepatic ET exchange was documented. However, a stimulated hepatic TNF-alpha release seems to be predictive of the beginning of liver dysfunction.

Citing Articles

7,8-dihydroxycoumarin has a dual mechanism of action in hepatic ischemia reperfusion injury.

Zhu H, Gao H, Zhang S Int J Clin Exp Pathol. 2015; 8(9):10121-9.

PMID: 26617719 PMC: 4637534.


Dual role of chloroquine in liver ischemia reperfusion injury: reduction of liver damage in early phase, but aggravation in late phase.

Fang H, Liu A, Dahmen U, Dirsch O Cell Death Dis. 2013; 4:e694.

PMID: 23807223 PMC: 3702304. DOI: 10.1038/cddis.2013.225.


Oxidation of HMGB1 causes attenuation of its pro-inflammatory activity and occurs during liver ischemia and reperfusion.

Liu A, Fang H, Dirsch O, Jin H, Dahmen U PLoS One. 2012; 7(4):e35379.

PMID: 22514737 PMC: 3325960. DOI: 10.1371/journal.pone.0035379.


Beta-glucan reflects liver injury after preservation and transplantation in dogs.

Katsuramaki T, Suzuki T, Zhu Y, Starzl T, Matsura S, Todo S J Invest Surg. 1999; 12(1):39-43.

PMID: 10084678 PMC: 2964274. DOI: 10.1080/089419399272755.


Protective effect of TNF-alpha and IL-1 beta inhibitor FR167653 on ischemia-reperfusion injury in rat small intestinal transplantation.

Yamada T, Murase N, Maeda T, Ye Q, Sakamoto T, Terakura M Transplant Proc. 1998; 30(6):2638.

PMID: 9745524 PMC: 2972713. DOI: 10.1016/s0041-1345(98)00760-x.